Respiratory Tract Diseases

568 trials 207 recruiting

Filter these 568 trials by phase, country and sponsor.

Open in Search →

A Phase 3 Study of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Ended

2024-514173-22-00 Cystic Fibrosis 5 2023-02-28
A Randomized Double-blind Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients with Idiopathic Pulm… Ended

2024-511330-13-00 Idiopathic Pulmonary Fibrosis 4 2023-01-17
An Interventional and Translational Study investigating Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With M… Ended

2024-510837-16-00 locally-advanced and unresectable or metastatic NSCLC w 4 2022-12-13
AFAMOSI: Prospective, randomized, multicenter Phase IV study to evaluate the efficacy and safety of afatinib followed by osimertinib compare… Ended

2024-511625-55-00 EGFRmutated/T790M Mutation negative non-squamous NSCLC 6 2022-11-30
OM 85 in Paediatric Recurrent Respiratory Tract Infections with Wheezing Lower Respiratory Illness Ended

2024-511581-37-00 Respiratory Tract Infections with Wheezing Lower Respir 6 2022-11-25
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor Long-term Safety and Efficacy in Subjects Without F508del Ended

2024-515637-14-00 Cystic Fibrosis 5 2022-11-08
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients with Uncontrolled Moderate to Sev… Ended

2024-513423-16-00 Asthma 6 2022-08-25
Clinical trial of statins CAncer preventive and Pleiotropic TherApy IN smokers with chronic obstructive pulmonary disease (COPD) Ended

2024-516714-37-00 Chronic obstructive pulmonary disease (COPD) 5 2022-01-19
Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st-line t… Ended

2024-517965-18-00 Advanced NSCLC with common EGFR-Mutation 4 2021-11-11
CORTICOP_Comparison of corticosteroids versus placebo on duration of ventilatory support during severe acute exacerbations of COPD patients … Ended

2024-516651-41-00 COPD : chronic obstructive Pulmonary disease 5 2021-10-08
Once-daily inhaled molgramostim nebulizer solution in aPAP Ended

2024-511052-41-00 Autoimmune Pulmonary Alveolar Proteinosis 5 2021-05-10
Breaking the big Five Barriers of Brain Metastasis: A prospective phase II, open-label, multi-center trial of combined nivolumab, ipilimumab… Ended

2024-512684-31-00 non-squamous nonsmall-cell lung cancer (NSCLC) metastat 4 2021-04-14
Exploratory study evaluating the potential of immune signature profiling for predicting response in patients with resectable Stage II, IIIA … Ended

2024-516590-75-00 Lung cancer 4 2021-02-22
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended

2023-507263-19-00 Advanced Non-Small Cell Lung Cancer 5 2020-12-23
Brentuximab Vedotin plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Ended

2023-503384-41-00 Relapsed or refractory diffuse large B-cell lymphoma (D 5 2020-12-22
Parent and/or Legal Guardian ICF and Adult patient ICF: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study wi… Ended

2022-501012-34-00 Pulmonary Arterial Hypertension 5 2020-02-27
Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab. Ended

2023-510248-19-00 Eosinophilic Granulomatosis with Polyangiitis (EGPA) 5 2020-01-21
Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study) Ended

2022-502604-67-00 Malignant pleural mesothelioma (MPM) 10 2019-12-20
The Effect of Benralizumab on Structural and Lung Function Changes in Patients with Severe Asthma Ended

2023-506614-40-00 Severe eosinophilic asthma 6 2019-11-11
A clinical study to confirm the doses of selexipag to be used in children with pulmonary arterial hypertension Ended

2022-503042-42-00 Pulmonary Arterial Hypertension 4 2018-07-23
A Study with an active treatment to Assess the Long-term Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Al… Ended

2024-513962-20-00 Pulmonary Emphysema due to Alpha-1-Antitrypsin Deficien 5 2016-07-14
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) Ended

2023-507889-89-00 Respiratory tract infection 5 2016-02-19
A Controlled Study with an active treatment and a Placebo to Assess the Efficacy and Safety of Weekly Intravenous Product in Subjects with P… Ended

2023-510030-83-00 Pulmonary Emphysema due to Alpha-1-Antitrypsin Deficien 5 2014-01-29
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients with Cystic Fibrosis Halted

2024-511184-28-00 Cystic fibrosis 4 2024-10-23